Return to search results
Vedolizumab
Entyvio (vedolizumab) is a prescription biologic medication that blocks certain immune cells from entering the gut, reducing inflammation. It's used to treat moderate to severe ulcerative colitis or Crohn's disease in adults who haven't responded well to other therapies. Available as an intravenous infusion (300 mg) or subcutaneous injection pen (108 mg/0.68 mL). This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Entyvio (vedolizumab) is a prescription biologic medication that blocks certain immune cells from entering the gut, reducing inflammation. It's used to treat moderate to severe ulcerative colitis or Crohn's disease in adults who haven't responded well to other therapies. Available as an intravenous infusion (300 mg) or subcutaneous injection pen (108 mg/0.68 mL). This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Vedolizumab",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Vedolizumab — ANDA 761133 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761133"
}
]
|
| identifier | ANDA761133 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"drug-safety",
"health-care",
"medications",
"pharmaceuticals"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Vedolizumab |
